Skip to main content
Top

17-06-2024 | Aplastic Anemia | ORIGINAL ARTICLE

Response to Immunosuppressive Therapy in Aplastic Anemia—A Single Centre, Prospective Study of 158 Patients from a Tertiary Care Centre in India

Authors: Mahathi Krishnan, Deepak Amalnath

Published in: Indian Journal of Hematology and Blood Transfusion

Login to get access

Abstract

Immunosuppressive therapy (IST) with Antithymocyte globulin (ATG) and cyclosporine is the therapy of choice in aplastic anemia (AA) patients who are more than 40 years of age and younger patients who do not have matched sibling donor for stem cell transplant (SCT). The overall response rate to IST is approximately 65%. The two preparations of ATG that are available in India are Atgam (Pfizer) and Thymogam (Bharat serum, India). Most of the published studies, from India, have used ATGAM. We present the largest study on IST (with Thymogam) from India. This is a single centre prospective study conducted in a tertiary care institute in southern India, from July 2016 to June 2022. All patients of age more than 13 years with diagnosis of aplastic anemia were included. Those with inherited bone marrow failure syndromes were excluded. Severity of AA and response rate was classified based on standard criteria. Patients were followed up till discharge and then monthly for at least 6 months. A total of 158 patients ( males-85, females- 73) received IST (Thymogam plus cyclosporine).Most of the patients had non severe AA(58%) followed by severe (28%) and very severe AA(14%). At 6 months post IST, the overall response rate (ORR) was 66% (complete response- 2% and partial response -64%) while the mortality rate was 13%.The ORR was 64% at 12 months and 61% at 24 months after IST. Age, Gender and severity at presentation did not influence response rates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172:187–207CrossRefPubMed Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172:187–207CrossRefPubMed
2.
go back to reference Mahapatra M, Singh PK, Agarwal M, Prabhu M, Mishra P, Seth T et al (2015) Epidemiology, clinico-haematological profile and management of aplastic anaemia: AIIMS experience. J Assoc Physicians India 63(3 Suppl):30–35PubMed Mahapatra M, Singh PK, Agarwal M, Prabhu M, Mishra P, Seth T et al (2015) Epidemiology, clinico-haematological profile and management of aplastic anaemia: AIIMS experience. J Assoc Physicians India 63(3 Suppl):30–35PubMed
3.
go back to reference George B, Mathews V, Viswabandya A, Abraham A, Ganapule A, Fouzia NA et al (2015) Immunosuppressive therapy and bone marrow transplantation for aplastic anaemia—the CMC experience. J Assoc Physicians India 63(3 Suppl):36–40PubMed George B, Mathews V, Viswabandya A, Abraham A, Ganapule A, Fouzia NA et al (2015) Immunosuppressive therapy and bone marrow transplantation for aplastic anaemia—the CMC experience. J Assoc Physicians India 63(3 Suppl):36–40PubMed
4.
go back to reference Amalnath DS (2020) Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India. Indian J Hematol Blood Transfus 36(3):473–476CrossRefPubMed Amalnath DS (2020) Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India. Indian J Hematol Blood Transfus 36(3):473–476CrossRefPubMed
5.
go back to reference Patel AB, Panchal HP, Anand AS, Patel AA, Parikh SP, Shah SA (2015) Acquired severe aplastic anemia treated with antithymocyte globulin and cyclosporine: an experience of regional cancer center, western India. J Appl Hematol 6:53–57CrossRef Patel AB, Panchal HP, Anand AS, Patel AA, Parikh SP, Shah SA (2015) Acquired severe aplastic anemia treated with antithymocyte globulin and cyclosporine: an experience of regional cancer center, western India. J Appl Hematol 6:53–57CrossRef
6.
go back to reference Sharma R, Chandra J, Sharma S, Pemde H, Singh V (2012) Antithymocyte globulin and cyclosporine in children with aplastic anemia: a developing country experience. J Pediatr Hematol Oncol 34:93–95CrossRefPubMed Sharma R, Chandra J, Sharma S, Pemde H, Singh V (2012) Antithymocyte globulin and cyclosporine in children with aplastic anemia: a developing country experience. J Pediatr Hematol Oncol 34:93–95CrossRefPubMed
7.
go back to reference Nair V, Sondhi V, Sharma A, Das S, Sharma S (2012) Survival after immunosuppressive therapy in children with aplastic anemia. Indian Pediatr 49:371–376CrossRefPubMed Nair V, Sondhi V, Sharma A, Das S, Sharma S (2012) Survival after immunosuppressive therapy in children with aplastic anemia. Indian Pediatr 49:371–376CrossRefPubMed
8.
go back to reference Nair V, Sharma A, Das S, Sondhi V, Sharma S (2013) Immunosuppressive therapy in adults with aplastic anaemia: single-institution experience from India. Postgrad Med J 89:508–515CrossRefPubMed Nair V, Sharma A, Das S, Sondhi V, Sharma S (2013) Immunosuppressive therapy in adults with aplastic anaemia: single-institution experience from India. Postgrad Med J 89:508–515CrossRefPubMed
9.
go back to reference Malhotra P, Bodh V, Gurumurthy GS, Datta AK, Varma N, Varma S (2015) Outcomes of immunosuppressant therapy with lower dose of antithymocyte globulin and cyclosporine in aplastic anemia. Hematology 20(4):239–244CrossRefPubMed Malhotra P, Bodh V, Gurumurthy GS, Datta AK, Varma N, Varma S (2015) Outcomes of immunosuppressant therapy with lower dose of antithymocyte globulin and cyclosporine in aplastic anemia. Hematology 20(4):239–244CrossRefPubMed
10.
go back to reference Ramzan M, Yadav SP, Zafar MSH, Dinand V, Sachdeva A (2014) Outcome of Pediatric Acquired Aplastic Anemia: A Developing World Experience. Pediatr Hematol Oncol 31(1):29–38CrossRefPubMed Ramzan M, Yadav SP, Zafar MSH, Dinand V, Sachdeva A (2014) Outcome of Pediatric Acquired Aplastic Anemia: A Developing World Experience. Pediatr Hematol Oncol 31(1):29–38CrossRefPubMed
11.
go back to reference Gupta V, Kumar A, Tilak V, Saini I, Bhatia B (2012) Immunosuppressive therapy in aplastic anemia. Indian J Pediatr 79(12):1587–1591CrossRefPubMed Gupta V, Kumar A, Tilak V, Saini I, Bhatia B (2012) Immunosuppressive therapy in aplastic anemia. Indian J Pediatr 79(12):1587–1591CrossRefPubMed
12.
go back to reference Agarwal MB, Jijina F, Shah S, Malhotra P, Damodar S, Ross C (2015) Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia. Indian J Hematol Blood Transfus 31:174–179CrossRefPubMed Agarwal MB, Jijina F, Shah S, Malhotra P, Damodar S, Ross C (2015) Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia. Indian J Hematol Blood Transfus 31:174–179CrossRefPubMed
13.
go back to reference Dutta B, Dolai TK, Mandal PK, Baul S, De R, Senthil K, Chakrabarti P (2021) Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India. Indian J Hematol Blood Transfus 37(2):197–203CrossRefPubMed Dutta B, Dolai TK, Mandal PK, Baul S, De R, Senthil K, Chakrabarti P (2021) Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India. Indian J Hematol Blood Transfus 37(2):197–203CrossRefPubMed
14.
go back to reference Shah S, Jain P, Shah K, Patel K, Parikh S, Patel A et al (2019) Immunosuppressive therapy for aplastic anemia: a single-center experience from western India. Ann hematol 98(1):41–46CrossRefPubMed Shah S, Jain P, Shah K, Patel K, Parikh S, Patel A et al (2019) Immunosuppressive therapy for aplastic anemia: a single-center experience from western India. Ann hematol 98(1):41–46CrossRefPubMed
Metadata
Title
Response to Immunosuppressive Therapy in Aplastic Anemia—A Single Centre, Prospective Study of 158 Patients from a Tertiary Care Centre in India
Authors
Mahathi Krishnan
Deepak Amalnath
Publication date
17-06-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01794-y

2024 ASCO Annual Meeting Coverage

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare